Cargando…

Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness

Idiopathic inflammatory myopathies (IIMs) are a heterogenous group of complex muscle diseases of unknown etiology. These diseases are characterized by progressive muscle weakness and damage, together with involvement of other organ systems. It is generally believed that the autoimmune response (auto...

Descripción completa

Detalles Bibliográficos
Autores principales: Rayavarapu, Sree, Coley, William, Kinder, Travis B, Nagaraju, Kanneboyina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681571/
https://www.ncbi.nlm.nih.gov/pubmed/23758833
http://dx.doi.org/10.1186/2044-5040-3-13
_version_ 1782273275357822976
author Rayavarapu, Sree
Coley, William
Kinder, Travis B
Nagaraju, Kanneboyina
author_facet Rayavarapu, Sree
Coley, William
Kinder, Travis B
Nagaraju, Kanneboyina
author_sort Rayavarapu, Sree
collection PubMed
description Idiopathic inflammatory myopathies (IIMs) are a heterogenous group of complex muscle diseases of unknown etiology. These diseases are characterized by progressive muscle weakness and damage, together with involvement of other organ systems. It is generally believed that the autoimmune response (autoreactive lymphocytes and autoantibodies) to skeletal muscle-derived antigens is responsible for the muscle fiber damage and muscle weakness in this group of disorders. Therefore, most of the current therapeutic strategies are directed at either suppressing or modifying immune cell activity. Recent studies have indicated that the underlying mechanisms that mediate muscle damage and dysfunction are multiple and complex. Emerging evidence indicates that not only autoimmune responses but also innate immune and non-immune metabolic pathways contribute to disease pathogenesis. However, the relative contributions of each of these mechanisms to disease pathogenesis are currently unknown. Here we discuss some of these complex pathways, their inter-relationships and their relation to muscle damage in myositis. Understanding the relative contributions of each of these pathways to disease pathogenesis would help us to identify suitable drug targets to alleviate muscle damage and also improve muscle weakness and quality of life for patients suffering from these debilitating muscle diseases.
format Online
Article
Text
id pubmed-3681571
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36815712013-06-14 Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness Rayavarapu, Sree Coley, William Kinder, Travis B Nagaraju, Kanneboyina Skelet Muscle Review Idiopathic inflammatory myopathies (IIMs) are a heterogenous group of complex muscle diseases of unknown etiology. These diseases are characterized by progressive muscle weakness and damage, together with involvement of other organ systems. It is generally believed that the autoimmune response (autoreactive lymphocytes and autoantibodies) to skeletal muscle-derived antigens is responsible for the muscle fiber damage and muscle weakness in this group of disorders. Therefore, most of the current therapeutic strategies are directed at either suppressing or modifying immune cell activity. Recent studies have indicated that the underlying mechanisms that mediate muscle damage and dysfunction are multiple and complex. Emerging evidence indicates that not only autoimmune responses but also innate immune and non-immune metabolic pathways contribute to disease pathogenesis. However, the relative contributions of each of these mechanisms to disease pathogenesis are currently unknown. Here we discuss some of these complex pathways, their inter-relationships and their relation to muscle damage in myositis. Understanding the relative contributions of each of these pathways to disease pathogenesis would help us to identify suitable drug targets to alleviate muscle damage and also improve muscle weakness and quality of life for patients suffering from these debilitating muscle diseases. BioMed Central 2013-06-07 /pmc/articles/PMC3681571/ /pubmed/23758833 http://dx.doi.org/10.1186/2044-5040-3-13 Text en Copyright © 2013 Rayavarapu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Rayavarapu, Sree
Coley, William
Kinder, Travis B
Nagaraju, Kanneboyina
Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness
title Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness
title_full Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness
title_fullStr Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness
title_full_unstemmed Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness
title_short Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness
title_sort idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681571/
https://www.ncbi.nlm.nih.gov/pubmed/23758833
http://dx.doi.org/10.1186/2044-5040-3-13
work_keys_str_mv AT rayavarapusree idiopathicinflammatorymyopathiespathogenicmechanismsofmuscleweakness
AT coleywilliam idiopathicinflammatorymyopathiespathogenicmechanismsofmuscleweakness
AT kindertravisb idiopathicinflammatorymyopathiespathogenicmechanismsofmuscleweakness
AT nagarajukanneboyina idiopathicinflammatorymyopathiespathogenicmechanismsofmuscleweakness